Lv HB, Wu QY, Zhang YJ, Quan SW, Ma N, Dai YQ, Sun Y. Study on the expression and prognostic relationship of MYL6B in liver cancer based on bioinformatics. World J Clin Oncol 2024; 15(9): 1188-1197 [PMID: 39351463 DOI: 10.5306/wjco.v15.i9.1188]
Corresponding Author of This Article
Yan Sun, MD, Chief Doctor, Department of General Surgery, Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu Road, Nangang District, Harbin 150000, Heilongjiang Province, China. sunyan202405@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Clinical and Translational Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Sep 24, 2024; 15(9): 1188-1197 Published online Sep 24, 2024. doi: 10.5306/wjco.v15.i9.1188
Study on the expression and prognostic relationship of MYL6B in liver cancer based on bioinformatics
Hai-Bing Lv, Qing-Yun Wu, Yu-Jiao Zhang, Sheng-Wei Quan, Ning Ma, Yu-Qing Dai, Yan Sun
Hai-Bing Lv, Sheng-Wei Quan, Department of General Surgery, Beidahuang Group General Hospital, Harbin 150000, Heilongjiang Province, China
Qing-Yun Wu, Department of General Surgery, Xianning Central Hospital, Xianning 437000, Hubei Province, China
Yu-Jiao Zhang, Department of Medical oncology, Beidahuang Group General Hospital, Harbin 150000, Heilongjiang Province, China
Ning Ma, Department of General Surgery, Daqing Oilfield General Hospital, Daqing 163000, Heilongjiang Province, China
Yu-Qing Dai, College of Clinical Medicine, Bengbu Medical University, Bengbu 233000, Anhui Province, China
Yan Sun, Department of General Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin 150000, Heilongjiang Province, China
Co-first authors: Hai-Bing Lv and Qing-Yun Wu.
Author contributions: Lv HB and Wu QY designed experiments, formal analysis, methodology and writing original draft; Zhang YJ and Quan SW contributed to data curation and methodology; Ma N provided resources; Dai YQ contributed to methodology; Sun Y contributed to conceptualization, project administration, supervision and writing; All authors read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Sun, MD, Chief Doctor, Department of General Surgery, Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu Road, Nangang District, Harbin 150000, Heilongjiang Province, China. sunyan202405@163.com
Received: May 7, 2024 Revised: July 21, 2024 Accepted: August 2, 2024 Published online: September 24, 2024 Processing time: 113 Days and 17.5 Hours
Abstract
BACKGROUND
Primary liver cancer is a prevalent and deadly cancer type. Despite treatment advances, prognosis remains poor, with high recurrence rates. Early detection is crucial but challenging due to the disease’s insidious nature. Myosin proteins play significant roles in cancer development, influencing cell migration, invasion, and tumor suppression. MYL6B, a myosin light chain, is involved in various cellular processes and has been associated with poor prognosis in colorectal adenocarcinoma and potential as a biomarker in breast cancer.
AIM
To investigate the expression of MYL6B in liver hepatocellular carcinoma (LIHC) and its impact on prognosis and potential mechanisms of action using bioinformatics methods.
METHODS
The expression of MYL6B in pan-cancer and normal tissues was analyzed using the gene expression profiling interactive analysis 2 and tumor immune estimation resource databases. The expression level of MYL6B in LIHC tissues and its relationship with prognosis were analyzed, immunohistochemical analysis of MYL6B and its effect on immune cell infiltration, and the protein network were further studied.
RESULTS
MYL6B was highly expressed in diffuse large b-cell lymphoma, LIHC, pancreatic adenocarcinoma, skin cutaneous melanoma, thymoma, uterine corpus endometrial carcinoma, uterine carcinosarcoma, and lowly expressed in kidney chromophobe, acute myeloid leukemia, testicular germ cell tumors. The expression level of MYL6B was significantly different between cancer and normal tissues. It had a significant impact on both overall survival and disease-free survival. MYL6B is highly expressed in hepatocellular carcinoma and its expression level increases with cancer progression. High MYL6B expression is associated with poor prognosis in terms of overall survival and recurrence-free survival. The immunohistochemical level of MYL6B is high in hepatocellular carcinoma tissues, and MYL6B has a high level of immune infiltration inflammation. In protein network analysis, MYL6B is correlated with MYL2, MYL6, MYL9, MYLK4, MYLK2, MYL12A, MYL12B, MYH11, MYH9 and MYH10.
CONCLUSION
The expression level of MYL6B in LIHC was significantly higher than in normal liver tissues, and it was correlated with the degree of differentiation survival rate, and immune infiltration. MYL6B is a potential target for LIHC treatment.
Core Tip: In the study, we employed advanced bioinformatics methodologies to meticulously scrutinize the intricate relationship between MYL6B and liver hepatocellular carcinoma (LIHC). It entailed a comprehensive analysis encompassing the contrasting expression patterns observed between LIHC and normal tissue samples, coupled with an intricate examination of how MYL6B expression levels correlate with the staging of cancer progression and the rates of survival. Furthermore, an exhaustive immunohistochemical investigation was conducted to elucidate the nuances of inflammation across varying levels of MYL6B expression in tissue specimens. The findings of this investigation unequivocally underscore MYL6B’s pivotal role as a prognostic determinant in hepatocellular carcinoma.
